CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

Core Insights - CDT Equity Inc. has identified a new biological target and therapeutic indication for its lead programme AZD1656, supported by positive pre-clinical trial data, affirming its AI-led drug repurposing strategy [1][3][4] - The company, in collaboration with Sarborg, utilized AI-powered disease mapping to analyze AZD1656 against a database of over 800 disease signatures, uncovering several new therapeutic indications [2][4] - The initial pre-clinical study results have validated the algorithmic findings, leading to plans for further studies to explore the commercial potential of the new biological target [3][4] Company Strategy - CDT has transitioned to a lean, disease-agnostic operating model informed by data-driven insights, successfully identifying novel indications for AZD1656 [4] - The company aims to progress AZD1656 towards a commercial out-licensing opportunity based on the positive outcomes of its research [4] Research and Development - Several pre-clinical studies have been initiated to explore the potential of AZD1656 in previously untapped therapeutic areas, leveraging a robust patent portfolio [2][3]